US 12,600,728 B2Granted

Interleukin-17 inhibitors

AssigneeNovartis AG

InventorsThomas Josef Troxler, David Orain, Pascal Furet, Klaus Weigand, Achim Schlapbach

Life of this patent

Estimating the term…

Abstract

The present invention relates to novel pyridine-N oxide substituted 2-formamido (N-phenyl and N-pyridyl) acetamide compounds that are Interleukin-17 (IL-17) inhibitors, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by IL-17.

Claims4

Dependent claims

A compound that is 2,4-dimethyl-3-(4-((S)-2-(1-methyl-1H-pyrazole-5-carboxamido)-2-((S)-1,2,3,4-tetrahydronaphthalen-1-yl)acetamido)phenyl)pyridine 1-oxide, or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application: 18/033,100Filed 1 Nov 2021
Priority: EP 202051212 Nov 2020
Published: US 2023/0391782 A17 Dec 2023
Granted: 14 Apr 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

C07D 487/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61K 31/4439
Containing further heterocyclic ring systems: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: non-condensed piperazines…
A61P 17/02
Drugs for dermatological disorders: for treating wounds, ulcers, burns, scars, keloids, or the like

Family

US 2023/0391782 A1Pre-grant publication · published 7 Dec 2023
US 12,600,728 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results